Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd, is a biotechnology company that develops and commercializes novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs and Jelmyto for pyelocalyceal solution. The company pipeline products include UGN-102, which treats non-muscle invasive urothelial cancer; UGN-301 for High-grade non-muscle-invasive bladder cancer. UroGen Pharma is headquartered in Ra Anana, Israel.
Headquarters
Israel
Address
9 Ha'Ta'Asiya St, Ra'Anana, Sharon (Netanya), 4365007
Website
www.urogen.com
Telephone
972 9 7707601
No of Employees
198
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
URGN (NASD)
Revenue (2022)
$82.7M
28.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
6.9%
(2022 vs 2021)
Market Cap*
$500.4M
Net Profit Margin (2022)
XYZ
27.5%
(2022 vs 2021)
* As of and is in US$
UroGen Pharma Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| UGN-102: Low-Grade Intermediate Non-muscle Invasive Bladder Cancer |
| UGN-301: High Grade Non-muscle Invasive Bladder Cancer |
Competitor Comparison
| Key Parameters | UroGen Pharma Ltd | Esperion Therapeutics Inc | Orthopaedics Northeast PC | Monarch HealthCare Inc |
|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | United States of America |
| City | Ra'Anana | Vero Beach | Angola | Irvine |
| State/Province | Sharon (Netanya) | Florida | Indiana | California |
| No. of Employees | 198 | 240 | - | - |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Arie Belldegrun, M.D | Chairman | Executive Board | - | 73 |
| Elizabeth Barrett | Chief Executive Officer; Director | Executive Board | - | 60 |
| Dong Kim | Chief Financial Officer | Senior Management | - | - |
| Jason Smith | Chief Compliance Officer; General Counsel | Senior Management | - | - |
| Mark P. Schoenberg, MD | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer